anti tf beads Search Results


N/A
Isolation of TCRγ/δ+ T cells directly from blood resulting in bead and label free cells
  Buy from Supplier

N/A
This antibody was obtained from a rabbit immunized with purified, recombinant Human Transferrin Receptor / TFRC / CD71 (rh Transferrin Receptor / TFRC / CD71; Catalog#11020-H07H; NP_003225.2; Cys89-Phe760).
  Buy from Supplier

99
Thermo Fisher hrp conjugated streptavidin
Hrp Conjugated Streptavidin, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+tf+beads/Streptavidin/pm28794432-170-22-24
Average 99 stars, based on 1 article reviews
hrp conjugated streptavidin - by Bioz Stars, 2026-09
99/100 stars
  Buy from Supplier

92
Santa Cruz Biotechnology goat elongin
Goat Elongin, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+tf+beads/Elongin+A+Antibody/pmc05800316-714-25-30
Average 92 stars, based on 1 article reviews
goat elongin - by Bioz Stars, 2026-09
92/100 stars
  Buy from Supplier

99
Thermo Fisher antibody tf histone dna complexes
Antibody Tf Histone Dna Complexes, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+tf+beads/DNA/pm29511024-300-0-15
Average 99 stars, based on 1 article reviews
antibody tf histone dna complexes - by Bioz Stars, 2026-09
99/100 stars
  Buy from Supplier

98
Bio-Rad anti tf beads
Anti Tf Beads, supplied by Bio-Rad, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+tf+beads/Tris/pm16439595-93-10-14
Average 98 stars, based on 1 article reviews
anti tf beads - by Bioz Stars, 2026-09
98/100 stars
  Buy from Supplier

92
OriGene tf tgfp
Tf Tgfp, supplied by OriGene, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+tf+beads/Mouse+Monoclonal+tGFP+Antibody%2C+Clone+OTI2H8%2C+Magnetic+Beads/pm38233821-104-30-44
Average 92 stars, based on 1 article reviews
tf tgfp - by Bioz Stars, 2026-09
92/100 stars
  Buy from Supplier

94
Santa Cruz Biotechnology monoclonal antibody against tf 10h10
Nanoparticle tracking analysis (NTA) of TF-containing microvesicles (1.03–1.08 g/ml) separated by density gradient centrifugation. Microvesicles were prepared from normal human plasma (A), conditioned media from MDA-MB-231 cells (B), and conditioned media from MDA-MB-231 cells expressing TF-tGFP protein (C). The plasma and conditioned media were collected and cleared of any cell debris by centrifuging at 5,400 g on a microcentrifuge, and microvesicles sedimented at 100,000 g . The microvesicles were resuspended in PBS and were fractionated by density gradient ultracentrifugation using a sucrose–OptiPrep gradient covering an approximate density range of 1.02–1.22 g/ml alongside 2 sets of DensityMarkerBeads. The samples were centrifuged at 52,000 g for 90 min at 20°C in a SW41Ti rotor on a Beckman L8-M ultracentrifuge. Following centrifugation, aliquots (0.5 ml) were sequentially removed and assessed for TF antigen. Samples containing TF antigen were then pooled (1.03–1.08 g/ml) and diluted 1:10 in PBS, and the size of the microvesicle population was analysed by NTA using a NanoSight LM10 instrument. A control sample was prepared by adding MDA-MB-231-derived microvesicles to the same pooled fractions from a blank density gradient centrifugation (D). A negative control made of the pooled fractions from a blank density gradient centrifugation showed no detectable trace (E). The illustrations are typical (n=3) of the size distributions which were determined using NTA software. The total amounts of microvesicles in the samples are not comparable. TF-containing microvesicles were immuno-purified from conditioned media of MDA-MB-231 (F) and A375 cell lines (G). The samples were incubated with a monoclonal antibody against TF <t>(10H10;</t> 4 µg/ml) followed by protein A-magnetic beads. The samples were washed with PBS and eluted in phosphate buffer containing NaCl (500 mM). The samples were analysed by NTA against a sample treated similarly but without the antibody.
Monoclonal Antibody Against Tf 10h10, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+tf+beads/TF+Antibody/pmc04134674-56-19-24
Average 94 stars, based on 1 article reviews
monoclonal antibody against tf 10h10 - by Bioz Stars, 2026-09
94/100 stars
  Buy from Supplier

93
R&D Systems magnetic beads
Nanoparticle tracking analysis (NTA) of TF-containing microvesicles (1.03–1.08 g/ml) separated by density gradient centrifugation. Microvesicles were prepared from normal human plasma (A), conditioned media from MDA-MB-231 cells (B), and conditioned media from MDA-MB-231 cells expressing TF-tGFP protein (C). The plasma and conditioned media were collected and cleared of any cell debris by centrifuging at 5,400 g on a microcentrifuge, and microvesicles sedimented at 100,000 g . The microvesicles were resuspended in PBS and were fractionated by density gradient ultracentrifugation using a sucrose–OptiPrep gradient covering an approximate density range of 1.02–1.22 g/ml alongside 2 sets of DensityMarkerBeads. The samples were centrifuged at 52,000 g for 90 min at 20°C in a SW41Ti rotor on a Beckman L8-M ultracentrifuge. Following centrifugation, aliquots (0.5 ml) were sequentially removed and assessed for TF antigen. Samples containing TF antigen were then pooled (1.03–1.08 g/ml) and diluted 1:10 in PBS, and the size of the microvesicle population was analysed by NTA using a NanoSight LM10 instrument. A control sample was prepared by adding MDA-MB-231-derived microvesicles to the same pooled fractions from a blank density gradient centrifugation (D). A negative control made of the pooled fractions from a blank density gradient centrifugation showed no detectable trace (E). The illustrations are typical (n=3) of the size distributions which were determined using NTA software. The total amounts of microvesicles in the samples are not comparable. TF-containing microvesicles were immuno-purified from conditioned media of MDA-MB-231 (F) and A375 cell lines (G). The samples were incubated with a monoclonal antibody against TF <t>(10H10;</t> 4 µg/ml) followed by protein A-magnetic beads. The samples were washed with PBS and eluted in phosphate buffer containing NaCl (500 mM). The samples were analysed by NTA against a sample treated similarly but without the antibody.
Magnetic Beads, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+tf+beads/Human+COUP-TF+I%2FNR2F1+Antibody+(Clone+H8132)/pm40011774-666-11-24
Average 93 stars, based on 1 article reviews
magnetic beads - by Bioz Stars, 2026-09
93/100 stars
  Buy from Supplier

N/A
Anti-Che-1 pS477 (AATF) (RABBIT) Antibody - 600-401-W99
  Buy from Supplier

N/A
Produced in rabbits immunized with E. coli-derived Human Gtf2f2 fragment, and purified by antigen affinity chromatography.
  Buy from Supplier

N/A
Lactoferrin LTF rabbit polyclonal antibody Azide Free
  Buy from Supplier

Image Search Results


Nanoparticle tracking analysis (NTA) of TF-containing microvesicles (1.03–1.08 g/ml) separated by density gradient centrifugation. Microvesicles were prepared from normal human plasma (A), conditioned media from MDA-MB-231 cells (B), and conditioned media from MDA-MB-231 cells expressing TF-tGFP protein (C). The plasma and conditioned media were collected and cleared of any cell debris by centrifuging at 5,400 g on a microcentrifuge, and microvesicles sedimented at 100,000 g . The microvesicles were resuspended in PBS and were fractionated by density gradient ultracentrifugation using a sucrose–OptiPrep gradient covering an approximate density range of 1.02–1.22 g/ml alongside 2 sets of DensityMarkerBeads. The samples were centrifuged at 52,000 g for 90 min at 20°C in a SW41Ti rotor on a Beckman L8-M ultracentrifuge. Following centrifugation, aliquots (0.5 ml) were sequentially removed and assessed for TF antigen. Samples containing TF antigen were then pooled (1.03–1.08 g/ml) and diluted 1:10 in PBS, and the size of the microvesicle population was analysed by NTA using a NanoSight LM10 instrument. A control sample was prepared by adding MDA-MB-231-derived microvesicles to the same pooled fractions from a blank density gradient centrifugation (D). A negative control made of the pooled fractions from a blank density gradient centrifugation showed no detectable trace (E). The illustrations are typical (n=3) of the size distributions which were determined using NTA software. The total amounts of microvesicles in the samples are not comparable. TF-containing microvesicles were immuno-purified from conditioned media of MDA-MB-231 (F) and A375 cell lines (G). The samples were incubated with a monoclonal antibody against TF (10H10; 4 µg/ml) followed by protein A-magnetic beads. The samples were washed with PBS and eluted in phosphate buffer containing NaCl (500 mM). The samples were analysed by NTA against a sample treated similarly but without the antibody.

Journal: Journal of Extracellular Vesicles

Article Title: Characterization of physical properties of tissue factor–containing microvesicles and a comparison of ultracentrifuge-based recovery procedures

doi: 10.3402/jev.v3.23592

Figure Lengend Snippet: Nanoparticle tracking analysis (NTA) of TF-containing microvesicles (1.03–1.08 g/ml) separated by density gradient centrifugation. Microvesicles were prepared from normal human plasma (A), conditioned media from MDA-MB-231 cells (B), and conditioned media from MDA-MB-231 cells expressing TF-tGFP protein (C). The plasma and conditioned media were collected and cleared of any cell debris by centrifuging at 5,400 g on a microcentrifuge, and microvesicles sedimented at 100,000 g . The microvesicles were resuspended in PBS and were fractionated by density gradient ultracentrifugation using a sucrose–OptiPrep gradient covering an approximate density range of 1.02–1.22 g/ml alongside 2 sets of DensityMarkerBeads. The samples were centrifuged at 52,000 g for 90 min at 20°C in a SW41Ti rotor on a Beckman L8-M ultracentrifuge. Following centrifugation, aliquots (0.5 ml) were sequentially removed and assessed for TF antigen. Samples containing TF antigen were then pooled (1.03–1.08 g/ml) and diluted 1:10 in PBS, and the size of the microvesicle population was analysed by NTA using a NanoSight LM10 instrument. A control sample was prepared by adding MDA-MB-231-derived microvesicles to the same pooled fractions from a blank density gradient centrifugation (D). A negative control made of the pooled fractions from a blank density gradient centrifugation showed no detectable trace (E). The illustrations are typical (n=3) of the size distributions which were determined using NTA software. The total amounts of microvesicles in the samples are not comparable. TF-containing microvesicles were immuno-purified from conditioned media of MDA-MB-231 (F) and A375 cell lines (G). The samples were incubated with a monoclonal antibody against TF (10H10; 4 µg/ml) followed by protein A-magnetic beads. The samples were washed with PBS and eluted in phosphate buffer containing NaCl (500 mM). The samples were analysed by NTA against a sample treated similarly but without the antibody.

Article Snippet: TF-containing microvesicles were also isolated directly from conditioned media of MDA-MB-231 and A375 cell lines, by immuno-precipitation using a monoclonal antibody against TF (10H10) (Santa Cruz Biotechnology, Heidelberg, Germany), followed by protein A magnetic beads (Miltenyi Biotec, Bisley, UK).

Techniques: Gradient Centrifugation, Clinical Proteomics, Expressing, Centrifugation, Control, Derivative Assay, Negative Control, Software, Purification, Incubation, Magnetic Beads